Alkermes Inc

Type: Company
Name: Alkermes Inc
Nationality: United States
Web Address: http://www.alkermes.com/
Fact Sheet: Fact Sheet for Alkermes Inc
First reported Apr 18 2014 - Updated Apr 18 2014 - 2 reports

Alkermes CEO Richard Pops on Building Big and Playing Well with Pharma

How do you build a biotech? Ask ten CEOs and you’ll likely get a hundred answers, but for Richard Pops, CEO of Waltham, MA- and Dublin, Ireland-based Alkermes, it arguably boils down to this: deliberately. Pops took over Alkermes (NASDAQ: ALKS)...Related ... [Published BioPortfolio - Apr 18 2014]
First reported Apr 17 2014 - Updated Apr 17 2014 - 3 reports

Alkermes (ALKS) Showing Bearish Technicals With Resistance At $46.86

Alkermes Inc (http://www.marketintelligencecenter.com/symbol/ALKS"ALKS) presents a trading opportunity that offers a 9.97% return in just 121 days.A covered call on Alkermes at the $46.00 level expiring on Aug. '14 offers an assigned return rate of 9.97% ... [Published Individual.com - Apr 17 2014]
Entities: Alkermes Inc
First reported Apr 17 2014 - Updated Apr 17 2014 - 1 reports

The Zacks Analyst Blog Highlights:GIlead, AbbVie, MannKind, Alkermes and Pharmacyclics

CHICAGOToday, Zacks is promoting its ''Buy'' stock recommendations. . Here are highlights from Wednesday's Analyst Blog:Biotech Stock RoundupThe biotech selloff continued last week with NASDAQ Biotechnology declining 4.46% and the NYSE ARCA Biotech Index ... [Published PR Newswire - Apr 17 2014]
First reported Apr 17 2014 - Updated Apr 17 2014 - 1 reports

STATISTICS CANADA : Logging, 2012

React to this article Date   Title <1m ago   DISCOVERY COMMUNICATIONS : Cupcake Digital and Discovery Communications' Latest App, Discovery Kids Dinosaur Puzzle & Play, Roars Into App Stores <1m ago   GREENE COUNTY BANCORP : Announces Quarterly ... [Published 4 Traders - Apr 17 2014]
First reported Apr 15 2014 - Updated Apr 15 2014 - 1 reports

The Biggest Biotech Wins of the Week

Another tough week for the biotechnology industry overshadowed impressive clinical results from several companies. Alkermes ( NASDAQ: ALKS     ) scored a big win in a difficult indication. Puma Biotechnology ( NYSE: PBYI     ) announced a high probability ... [Published Motley Fool Discussion Boards - Apr 15 2014]
First reported Apr 09 2014 - Updated Apr 10 2014 - 4 reports

Alkermes Phase III trial of schizophrenia drug aripiprazole lauroxil meets primary endpoint

Irish based biopharmaceutical company Alkermes has reported positive topline results from a randomized, double-blind, placebo-controlled Phase III clinical trial of its new, long-acting injectable ... ... [Published Big News Network - Apr 10 2014]
First reported Apr 10 2014 - Updated Apr 10 2014 - 3 reports

Potential Alkermes (ALKS) Trade Has 6.41% Downside Protection

Alkermes Inc (http://www.marketintelligencecenter.com/symbol/ALKS"ALKS) presents a trading opportunity that offers a 8.62% return in just 128 days.A covered call on Alkermes at the $46.00 level expiring on Aug. '14 offers an assigned return rate of 8.62% ... [Published Individual.com - Apr 10 2014]
Entities: Alkermes Inc
First reported Apr 09 2014 - Updated Apr 09 2014 - 8 reports

Health Care Stocks Technical Coverage -- Research on Valeant Pharma Intl., Alkermes, Delcath Systems, and Acura Pharma

-- /PRNewswire/ --On Tuesday, April 08, 2014, the NASDAQ Composite ended at 4,112.99, up 0.81%, the Dow Jones Industrial Average edged 0.06% higher to finish the day at 16,256.14, and the S&P 500 closed at 1,851.96, up 0.38%. The gains were broad based ... [Published Sacramento Bee - Apr 09 2014]
First reported Apr 08 2014 - Updated Apr 09 2014 - 33 reports

Alkermes drug meets clinical study’s goal

Continue reading belowAlkermes PLC was a bright spot among the biotechs — the sector has been more than a bit volatile lately — after the company said its experimental drug to treat schizophrenia symptoms, aripiprazole lauroxil, met the main goal in a ... [Published Boston Globe - Apr 09 2014]
First reported Apr 07 2014 - Updated Apr 08 2014 - 3 reports

Alkermes (ALKS) Showing Bearish Technicals With Resistance At $43.49

The patented option trade-picking algorithms behind MarketIntelligenceCenter.com's Artificial Intelligence Center have selected a covered call trade on Alkermes Inc (http://www.marketintelligencecenter.com/symbol/ALKS"ALKS) that includes 9.25% downside ... [Published Individual.com - Apr 08 2014]
First reported Mar 21 2014 - Updated Mar 21 2014 - 8 reports

Reviewing the Top Health Care Equities -- Research on IntelliPharmaCeutics, Delcath Systems, Valeant Pharma and Alkermes

/PRNewswire/ --On Thursday, March 20, 2014 , the NASDAQ Composite ended at 4,319.29, up 0.27%, the Dow Jones Industrial Average gained 0.67% to reach 16,331.05, and the S&P 500 closed at 1,872.01, up 0.60%. The gains were broad based as nine of ten sectors ... [Published PharmaDiversity - Mar 21 2014]
First reported Mar 21 2014 - Updated Mar 21 2014 - 96 reports

Reviewing the Top Health Care Equities -- Research on IntelliPharmaCeutics, Delcath Systems, Valeant Pharma and Alkermes

/PRNewswire/ --On Thursday, March 20, 2014, the NASDAQ Composite ended at 4,319.29, up 0.27%, the Dow Jones Industrial Average gained 0.67% to reach 16,331.05, and the S&P 500 closed at 1,872.01, up 0.60%. The gains were broad based as nine of ten sectors ... [Published Nasdaq - Mar 21 2014]

Quotes

Original Article: NEXT ARTICLE More From BioPortfolio on "Alkermes CEO Richard Pops on Building Big and Playing Well with Pharma"
...lot in biotech, but it's also worth remembering a quote (apocryphally attributed to former Dallas Cowboys defensive lineman Randy White) that goes "potential is a fancy French word that means you haven't done yet"
Alkermes Inc (http://www.marketintelligencecenter.com/symbol/ALKS "ALKS) presents a trading opportunity that offers a 9.97% return in just 121 days."
"We were trying to find a way of dealing with opiate withdrawal and facilitate people to the next stage of addiction treatment" lead author Gregory Rudolf, MD, from the Swedish Addiction

More Content

All (408) | News (360) | Reports (0) | Blogs (37) | Audio/Video (0) | Fact Sheets (1) | Press Releases (10)
sort by: Date | Relevance
Alkermes CEO Richard Pops on Building Big and P... [Published BioPortfolio - Apr 18 2014]
Alkermes CEO Richard Pops on Building Big and P... [Published Xconomy - Apr 18 2014]
Xenoport's Path Is Long, But The Potential Is T... [Published Seeking Alpha - Apr 18 2014]
Alkermes (ALKS) Showing Bearish Technicals With... [Published Individual.com - Apr 17 2014]
The Zacks Analyst Blog Highlights:GIlead, AbbVi... [Published PR Newswire - Apr 17 2014]
STATISTICS CANADA : Logging, 2012 [Published 4 Traders - Apr 17 2014]
Alcoholism rehab leader forays into $23B opium ... [Published GantDaily.com - Apr 17 2014]
Alkermes (ALKS) Showing Bearish Technicals With... [Published MarketIntelligenceCenter.com - Apr 17 2014]
Alkermes Plc Stock Rating Lowered by Zacks (ALKS) [Published Mideast Time - Apr 17 2014]
Research and Markets: Aripiprazole Lauroxil (Sc... [Published Business Wire Professional Services News - Apr 17 2014]
Research and Markets: Aripiprazole Lauroxil (Sc... [Published Business Wire Health News - Apr 17 2014]
Alkermes Plc Lowered to Neutral at Zacks (ALKS) [Published American Banking News - Stock Ratings - Apr 17 2014]
Novel Nonopioid Approach Promising for Opioid D... [Published Diabetes Care - Apr 16 2014]
"Polymer-Based Sustained Release Device" in Pat... [Published Pharmacy Choice - Apr 16 2014]
Potential Alkermes (ALKS) Trade Has 7.94% Downs... [Published MarketIntelligenceCenter.com - Apr 16 2014]
The Biggest Biotech Wins of the Week [Published Motley Fool Discussion Boards - Apr 15 2014]
Alkermes (ALKS) Showing Bearish Technicals [Published MarketIntelligenceCenter.com - Apr 15 2014]
Wide Variability in State Access to SUD Meds [Published American Journal of Public Health - Apr 14 2014]
Alkermes (ALKS) Showing Bearish Technicals With... [Published MarketIntelligenceCenter.com - Apr 14 2014]
Alkermes Issues Positive Phase 3 Study Results [Published HighBeam Research - Apr 12 2014]
This Week in Biotech: The Questcor Buyout and M... [Published Motley Fool Discussion Boards - Apr 12 2014]
Insider Selling: Alkermes Plc CFO Sells 7,000 S... [Published Mideast Time - Apr 12 2014]
Insider Selling: Alkermes Plc CFO Sells 7,000 S... [Published American Banking News - Apr 12 2014]
Fix the Debt winds down lobbying presence — Few... [Published Politico - Apr 11 2014]
East Coast Biotech Roundup: Agios, Spero, Cerul... [Published Xconomy - Apr 11 2014]
Priority Reviews, Preliminary Earnings Releases... [Published Finwin - Apr 11 2014]
Priority Reviews, Preliminary Earnings Releases... [Published Financial Services - Apr 11 2014]
MKM Partners Increases Alkermes Plc Price Targe... [Published Zolmax News - Apr 11 2014]
For Heroin, Testing A New Drug Treatment And ‘P... [Published WBUR - Apr 11 2014]
Let's Get the Facts Straight About Zohydro' ER-... [Published FinanzNachrichten.de - Apr 11 2014]
1 2 3 4 5 6 7 8 9 10 ...
In Focus
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
Content Volume
Document Volume
Network
Network

Blogs

sort by: Date | Relevance
Alkermes (ALKS) Showing Bearish Technicals With... [Published MarketIntelligenceCenter.com - Apr 17 2014]
Alkermes Inc (ALKS) presents a trading opportunity that offers a 9.97% return in just 121 days.A covered call on Alkermes at the $46.00 level expiring on Aug. '14 offers an assigned return rate of 9.97% or 30.07% annualized. This trade offers 7.11% downside ...
Research and Markets: Aripiprazole Lauroxil (Sc... [Published Business Wire Professional Services News - Apr 17 2014]
DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/t528kt/aripiprazole) has announced the addition of the "Aripiprazole Lauroxil (Schizophrenia) - Forecast and Market Analysis to 2022" report to their offering. Aripiprazole ...
Research and Markets: Aripiprazole Lauroxil (Sc... [Published Business Wire Health News - Apr 17 2014]
DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/t528kt/aripiprazole) has announced the addition of the "Aripiprazole Lauroxil (Schizophrenia) - Forecast and Market Analysis to 2022" report to their offering. Aripiprazole ...
Potential Alkermes (ALKS) Trade Has 7.94% Downs... [Published MarketIntelligenceCenter.com - Apr 16 2014]
MarketIntelligenceCenter.com's option-trade picking algorithms have identified an attractive covered-call trade on Alkermes Inc (ALKS). Look at the Aug. '14 $44.00 covered call for a net debit in the $39.43 area. This trade has a duration of 122 days. ...
Alkermes (ALKS) Showing Bearish Technicals [Published MarketIntelligenceCenter.com - Apr 15 2014]
The patented option-trade picking algorithms that power MarketIntelligenceCenter.com's Artificial Intelligence Center have selected a covered-call trade on Alkermes Inc (ALKS) that includes 8.23% downside protection. Sell one contract of the Aug. '14 ...
1 2 3 4 5 6 7 8

Press Releases

sort by: Date | Relevance
Priority Reviews, Preliminary Earnings Releases... [Published Financial Services - Apr 11 2014]
Certifications, Authorizations, Stock Updates, ... [Published Financial Services - Apr 10 2014]
Health Care Stocks Technical Coverage -- Resear... [Published Financial Services - Apr 09 2014]
Gain Capital Holdings, Vail Resorts, Johnson & ... [Published Financial Services - Mar 24 2014]
Reviewing the Top Health Care Equities -- Resea... [Published Financial Services - Mar 21 2014]
1 2
Contact Us
Sales
Support


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2014 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.